IDWeek 2017

AWG Member Company Participation at IDWeek 2017

Thirteen AWG member companies presented data from their clinical and research programs at IDWeek 2017 taking which took place in San Diego from October 4 – 8, 2017. In addition to 59 poster presentations, representatives from AWG member companies participated in various panels and symposiums addressing the state of the antimicrobial development pipeline.

IDWeek is an annual scientific meeting that brings together infectious disease professionals to present and discuss the latest approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases.

 

Wednesday, October 4th

Affiliated Event
Time: 7:00 AM – 8:00 AM
Room: 09
T2Sepsis Solution: The Impact of Direct from Whole Blood Diagnostics on the Management of Bloodstream Infections (T2Candida and the T2Bacteria RUO Panel) https://idsa.confex.com/idsa/2017/webprogram/Session9585.html

  • T2 Biosystems

Thursday, October 5th

Poster Abstract Session
Time: 12:30 PM – 2:00 PM
Room: Poster Hall CD

HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens
Iterum Therapeutics:

Emerging Resistance – Epidemiology and Mechanisms
Melinta Therapeutics:

Theravance Biopharma:

Clinical: Bone and Joint Infection
Theravance Biopharma:

Fungus Among Us: Basic Science
Viamet Pharmaceuticals:

Symposium
Time: 2:00 PM – 3:00 PM
Room: 20ABCD
New Antibiotics: What’s in the Pipeline https://idsa.confex.com/idsa/2017/webprogram/Session8957.html

Melinta Therapeutics:
Time:  2:00 PM

Zavante Therapeutics:
Time: 2:09 PM

Paratek Pharmaceuticals:
Time: 2:36 PM

Nabriva Therapeutics:
Time: 2:45 PM

Friday, October 6th

Meet the Professor Session
Time: 7:00 AM – 8:15 AM
Room: 06DE
Pipeline 2.0 https://idsa.confex.com/idsa/2017/webprogram/Session9191.html
AWG Panelists:

  • Sue K. Cammarata, MD – Melinta Therapeutics
  • Evelyn J. Ellis-Grosse, Ph.D. – Zavante Therapeutics, Inc.
  • Paul McGovern, MD – Paratek Pharmaceuticals
  • Steven P. Gelone, PharmD – Nabriva Therapeutics AG

Poster Abstract Session
Time: 12:30 PM – 2:00 PM
Room: Poster Hall CD

Adult Immunization – Miscellaneous
Arsanis:

Preclinical Study with New Antibiotics and Antifungals
Amplyx Pharmaceuticals:

Cidara Therapeutics:

Melinta Therapeutics:

Nabriva Therapeutics:

Paratek Pharmaceuticals:

Scynexis:

Zavante Therapeutics:

Expanded Spectrum – New Antimicrobial Susceptibility Testing
Contrafect Corporation:

Melinta Therapeutics:

Nabriva Therapeutics:

Paratek Pharmaceuticals:

Scynexis:

Zavante Therapeutics:

Saturday, October 7th

Oral Abstract Session
Time: 8:30 AM – 10:00 AM
Room: 01AB

The Fungus Among-us – Clinical Advances
T2 Biosystems:

Poster Abstract Session
Time: 12:30 PM – 2:00 PM
Room: Poster Hall CD

Clinical Study with New Antibiotics and Antifungals
Arsanis:

  • 1844. Prevention of Lung Pathology and Mortality in Rabbit Staphylococcus aureus Pneumonia with Cytotoxin-Neutralizing Monoclonal IgGs that Penetrate Epithelial Lining Fluid
  • 1849. Population Pharmacokinetic Model for Intravenous ASN100 in Healthy Subjects
    • https://idsa.confex.com/idsa/2017/webprogram/Paper64041.html

Amplyx Pharmaceuticals:

Iterum Therapeutics:

Melinta Therapeutics:

Paratek Pharmaceuticals:

Theravance Biopharma:

Zavante Therapeutics:

  • 1830. Phenotypic Antibiotic Resistance in ZEUS: A Multi-center, Randomized, Double-Blind Phase 2/3 Study of ZTI-01 versus Piperacillin-Tazobactam (P-T) in the Treatment of Patients with Complicated Urinary Tract Infections (cUTI) including Acute Pyelonephritis (AP)
  • 1833. Per Pathogen Outcomes from the ZEUS study, a Multi-center, Randomized, Double-Blind Phase 2/3 Study of ZTI-01 (fosfomycin for injection) versus Piperacillin-Tazobactam (P-T) in the Treatment of Patients with Complicated Urinary Tract Infections (cUTI) including Acute Pyelonephritis (AP)
  • 1837. Safety Results from the ZEUS Study: Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP) who Received
  • 1845. Intravenous Fosfomycin (ZTI-01) for the Treatment of Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP): Results from a Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults (ZEUS)
  • 1848. Population Pharmacokinetic (PPK) Analysis of ZTI-01 (Fosfomycin for Injection) Using Data from Healthy Subjects and Patients with Complicated Urinary Tract Infections (cUTI)

Diagnostics – Mycology
T2 Biosystems:

Stewardship: Impact of Diagnostics
T2 Biosystems: